Levin Capital Strategies L.P. Has $22.60 Million Position in Becton, Dickinson and Company $BDX

Levin Capital Strategies L.P. raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 66.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 143,713 shares of the medical instruments supplier’s stock after buying an additional 57,232 shares during the period. Becton, Dickinson and Company comprises about 1.7% of Levin Capital Strategies L.P.’s portfolio, making the stock its 15th biggest position. Levin Capital Strategies L.P.’s holdings in Becton, Dickinson and Company were worth $22,596,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. Empowered Funds LLC increased its position in shares of Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after buying an additional 1,354 shares during the period. United Bank increased its position in shares of Becton, Dickinson and Company by 23.9% during the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after buying an additional 993 shares during the period. Marshall Wace LLP raised its stake in Becton, Dickinson and Company by 365.1% during the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after buying an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in Becton, Dickinson and Company by 34.7% in the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock valued at $4,048,000 after buying an additional 6,058 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Zacks Research raised shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. TD Cowen dropped their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research note on Monday, May 4th. The Goldman Sachs Group cut their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Finally, Weiss Ratings downgraded Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $180.29.

Insider Activity at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 5,188 shares of company stock worth $765,120. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.4%

BDX opened at $153.23 on Thursday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market cap of $42.22 billion, a P/E ratio of 38.79, a price-to-earnings-growth ratio of 10.89 and a beta of 0.21. The company has a fifty day moving average price of $149.52 and a two-hundred day moving average price of $165.32.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts predict that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th were paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.